Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma
出版年份 2013 全文链接
标题
Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma
作者
关键词
-
出版物
Annals of the New York Academy of Sciences
Volume 1291, Issue 1, Pages 1-13
出版商
Wiley
发表日期
2013-06-18
DOI
10.1111/nyas.12180
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study
- (2013) S. F. Slovin et al. ANNALS OF ONCOLOGY
- Vemurafenib in melanoma
- (2013) Heather M Shaw et al. Expert Review of Anticancer Therapy
- Tremelimumab: a review of development to date in solid tumors
- (2013) Ahmad A Tarhini Immunotherapy
- Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma
- (2013) Antoni Ribas et al. JOURNAL OF CLINICAL ONCOLOGY
- Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial†
- (2012) M. Reck et al. ANNALS OF ONCOLOGY
- Immuno-oncology: understanding the function and dysfunction of the immune system in cancer
- (2012) O. J. Finn ANNALS OF ONCOLOGY
- Assessment of association between BRAF-V600E mutation status in melanomas and clinical response to ipilimumab
- (2012) Vafa Shahabi et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- CTLA-4 Blockade with Ipilimumab: Long-term Follow-up of 177 Patients with Metastatic Melanoma
- (2012) P. A. Prieto et al. CLINICAL CANCER RESEARCH
- Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study
- (2012) Thomas J. Lynch et al. JOURNAL OF CLINICAL ONCOLOGY
- Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
- (2012) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial
- (2012) Anna Maria Di Giacomo et al. LANCET ONCOLOGY
- Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial
- (2012) Kim Margolin et al. LANCET ONCOLOGY
- Two Hundred Years of Cancer Research
- (2012) Vincent T. DeVita et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma
- (2012) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Raising the Bar: The Curative Potential of Human Cancer Immunotherapy
- (2012) S. A. Rosenberg Science Translational Medicine
- The confluence of radiotherapy and immunotherapy
- (2012) Byron Burnette et al. Frontiers in Oncology
- Patient Responses to Ipilimumab, a Novel Immunopotentiator for Metastatic Melanoma
- (2011) Gregory K. Pennock et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- New drugs in melanoma: It’s a whole new world
- (2011) Alexander M.M. Eggermont et al. EUROPEAN JOURNAL OF CANCER
- Ipilimumab Increases Activated T Cells and Enhances Humoral Immunity in Patients With Advanced Melanoma
- (2011) Jeffrey S. Weber et al. JOURNAL OF IMMUNOTHERAPY
- A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma
- (2011) Omid Hamid et al. Journal of Translational Medicine
- A methodological framework to enhance the clinical success of cancer immunotherapy
- (2011) Axel Hoos et al. NATURE BIOTECHNOLOGY
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- (2011) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Systematic Review of Medical Treatment in Melanoma: Current Status and Future Prospects
- (2011) C. Garbe et al. ONCOLOGIST
- Advances in systemic treatment of melanoma
- (2010) A. M. M. Eggermont ANNALS OF ONCOLOGY
- Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study
- (2010) S. J. O'Day et al. ANNALS OF ONCOLOGY
- Cancer Statistics, 2010
- (2010) A. Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Current and future adjuvant immunotherapies for melanoma: Blockade of cytotoxic T-lymphocyte antigen-4 as a novel approach
- (2010) Sanjiv S. Agarwala et al. CANCER TREATMENT REVIEWS
- A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma
- (2010) Evan M. Hersh et al. INVESTIGATIONAL NEW DRUGS
- Improved Endpoints for Cancer Immunotherapy Trials
- (2010) A. Hoos et al. JNCI-Journal of the National Cancer Institute
- Novel immunotherapies as potential therapeutic partners for traditional or targeted agents: cytotoxic T-lymphocyte antigen-4 blockade in advanced melanoma
- (2010) Sanjiv S. Agarwala MELANOMA RESEARCH
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Development of Ipilimumab: Contribution to a New Paradigm for Cancer Immunotherapy
- (2010) Axel Hoos et al. SEMINARS IN ONCOLOGY
- Update on Immunologic Therapy With Anti–CTLA-4 Antibodies in Melanoma: Identification of Clinical and Biological Response Patterns, Immune-Related Adverse Events, and Their Management
- (2010) Katharina C. Kaehler et al. SEMINARS IN ONCOLOGY
- CTLA-4 blockade: therapeutic potential in cancer treatments
- (2010) Ahmad Tarhini OncoTargets and Therapy
- Cancer Prevention: From 1727 to Milestones of the Past 100 Years
- (2009) Scott M. Lippman et al. CANCER RESEARCH
- Do We Need a Different Set of Response Assessment Criteria for Tumor Immunotherapy?
- (2009) A. Ribas et al. CLINICAL CANCER RESEARCH
- A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma
- (2009) J. Weber et al. CLINICAL CANCER RESEARCH
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
- (2009) J. D. Wolchok et al. CLINICAL CANCER RESEARCH
- Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study
- (2009) Jedd D Wolchok et al. LANCET ONCOLOGY
- Human natural killer cells
- (2008) M. A. Caligiuri BLOOD
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
- Meta-Analysis of Phase II Cooperative Group Trials in Metastatic Stage IV Melanoma to Determine Progression-Free and Overall Survival Benchmarks for Future Phase II Trials
- (2008) Edward L. Korn et al. JOURNAL OF CLINICAL ONCOLOGY
- Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection
- (2008) Shawn D Blackburn et al. NATURE IMMUNOLOGY
- Cancer Immunology
- (2008) Olivera J. Finn NEW ENGLAND JOURNAL OF MEDICINE
- Radiotherapy augments the immune response to prostate cancer in a time-dependent manner
- (2008) Timothy J. Harris et al. PROSTATE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More